Trial Profile
OXiGENE OXC402-201: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Biological Effects of Intravenous Fosbretabulin in Asian Subjects With Polypoidal Choroidal Vasculopathy (PCV)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2016
Price :
$35
*
At a glance
- Drugs Fosbretabulin (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Therapeutic Use
- Sponsors OXiGENE
- 12 Apr 2014 New trial record